

110TH CONGRESS  
1ST SESSION

# H. R. 322

To derive human pluripotent stem cell lines using techniques that do not harm human embryos.

---

## IN THE HOUSE OF REPRESENTATIVES

JANUARY 9, 2007

Mr. BARTLETT of Maryland (for himself, Mr. GINGREY, Mr. WELLER, Mr. CHABOT, Mr. LIPINSKI, Mr. DAVIS of Kentucky, Mr. LINCOLN DAVIS of Tennessee, Mr. FRANKS of Arizona, Mr. HUNTER, Mrs. MUSGRAVE, Mr. JONES of North Carolina, Mr. INGLIS of South Carolina, and Mr. GILCHREST) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To derive human pluripotent stem cell lines using techniques that do not harm human embryos.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Alternative Pluripotent  
5 Stem Cell Therapies Enhancement Act of 2007”.

6 **SEC. 2. PURPOSES.**

7 It is the purpose of this Act to—

1           (1) intensify research that may result in im-  
2           proved understanding of or treatments for diseases  
3           and other adverse health conditions; and

4           (2) promote the derivation of pluripotent stem  
5           cell lines, including from postnatal sources, without  
6           creating human embryos for research purposes or  
7           discarding, destroying, or harming a human embryo  
8           or fetus.

9   **SEC. 3. ALTERNATIVE HUMAN PLURIPOTENT STEM CELL**  
10                                   **RESEARCH.**

11           Part B of title IV of the Public Health Service Act  
12           (42 U.S.C. 284 et seq.) is amended by inserting after sec-  
13           tion 409I the following:

14   **“SEC. 409J. ALTERNATIVE HUMAN PLURIPOTENT STEM**  
15                                   **CELL RESEARCH.**

16           “(a) IN GENERAL.—In accordance with section 492,  
17           the Secretary shall conduct and support basic and applied  
18           research to develop techniques for the isolation, derivation,  
19           production, or testing of stem cells that, like embryonic  
20           stem cells, are capable of producing all or almost all of  
21           the cell types of the developing body and may result in  
22           improved understanding of or treatments for diseases and  
23           other adverse health conditions, but are not derived from  
24           a human embryo.

1       “(b) GUIDELINES.—Not later than 90 days after the  
2 date of the enactment of this section, the Secretary, after  
3 consultation with the Director of the National Institutes  
4 of Health, shall issue final guidelines to implement sub-  
5 section (a), that—

6           “(1) provide guidance concerning the next steps  
7 required for additional research, which shall include  
8 a determination of the extent to which specific tech-  
9 niques may require additional basic or animal re-  
10 search to ensure that any research involving human  
11 cells using these techniques would clearly be con-  
12 sistent with the standards established under this sec-  
13 tion;

14           “(2) prioritize research with the greatest poten-  
15 tial for near-term clinical benefit; and

16           “(3) consistent with subsection (a), take into  
17 account techniques outlined by the President’s Coun-  
18 cil on Bioethics and any other appropriate tech-  
19 niques and research.

20       “(c) REPORTING REQUIREMENTS.—Not later than  
21 January 1 of each year, the Secretary shall prepare and  
22 submit to the appropriate committees of the Congress a  
23 report describing the activities carried out under this sec-  
24 tion during the fiscal year, including a description of the  
25 research conducted under this section.

1       “(d) RULE OF CONSTRUCTION.—Nothing in this sec-  
2 tion shall be construed to affect any policy, guideline, or  
3 regulation regarding embryonic stem cell research, human  
4 cloning by somatic cell nuclear transfer, or any other re-  
5 search not specifically authorized by this section.

6       “(e) DEFINITION.—In this section, the term ‘human  
7 embryo’ includes any organism, not protected as a human  
8 subject under part 46 of title 45, Code of Federal Regula-  
9 tions, as of the date of the enactment of the Alternative  
10 Pluripotent Stem Cell Therapies Enhancement Act of  
11 2007, that is derived by fertilization, parthenogenesis,  
12 cloning, or any other means from one or more human  
13 gametes or human diploid cells

14       “(f) AUTHORIZATION OF APPROPRIATIONS.—There  
15 are authorized to be appropriated such sums as may be  
16 necessary for each of fiscal years 2008 through 2010, to  
17 carry out this section.”.

○